<DOC>
	<DOCNO>NCT03037203</DOCNO>
	<brief_summary>This study 4-week , multicenter , randomize , double-blind , placebo-controlled , ascend dose , 4-period crossover study design evaluate safety , tolerability , efficacy , PK JZP-110 ( 75 , 150 , 300 mg ) treatment excessive sleepiness adult subject idiopathic PD .</brief_summary>
	<brief_title>A 4-Week Study Safety , Efficacy , Pharmacokinetics JZP-110 ( R ) -2-amino-3-phenylpropylcarbamate Hydrochloride Subjects With Parkinson 's Disease Excessive Sleepiness</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Disorders Excessive Somnolence</mesh_term>
	<criteria>1 . Diagnosis idiopathic PD accord UK PDS Brain Bank Criteria . 2 . Hoehn Yahr stage 1 , 2 , 3 . 3 . Baseline ESS score &gt; 10 . 4 . Baseline mean sleep latency â‰¤20 minute MWT . 1 . Diagnosis degenerative Parkinsonian syndrome ( e.g. , progressive supranuclear palsy , multiple system atrophy [ MSA ] , dementia Lewy body [ DLB ] ) . 2 . Usual nightly time bed &lt; 6 hour , include night Baseline visit . 3 . Prior documented history moderate severe obstructive sleep apnea ( OSA ) . 4 . Has evidence screen severe cognitive impairment cognitive impairment opinion investigator would prevent completion study procedure ability provide inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>